NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Biomarkers to Classify Heart Failure
Biomarkers to Classify Heart Failure

NCT02347722

Active Not RecruitingN/A

Sponsor: Ottawa Heart Institute Research Corporation

Conditions: Heart Failure

Countries: Canada

The purpose of this study is to evaluate existing biomarkers and see if they can be used to accurately diagnose the etiology of heart failure.

Eligibility overview

Sex: ALL

Age: 18 Years to

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Patients admitted with symptomatic heart failure, diagnosed within 2 years.
* Diagnosis of congestive heart failure using the modified Framingham criteria:

Simultaneous presence of at least 2 major criteria or 1 major criterion in conjunction with 2 minor criteria or a previous clear diagnosis of heart failure.

Major criteria:

* Paroxysmal nocturnal dyspnea or orthopnea
* Neck vein distention
* Rales/Crackles (\>10 cm from base of lungs)
* Acute pulmonary edema
* S3 gallop
* Increased central venous pressure (\>16 cm H2O at right atrium)
* Hepatojugular reflux
* Weight loss \>4.5 kg in 5 days in response to treatment Echocardiographic left ventricular dysfunction

Minor criteria:

* Bilateral ankle edema
* Nocturnal cough
* Dyspnea on exertion
* Hepatomegaly
* Pleural effusion
* Weight loss \>4.5 kg caused by heart failure where factors other than treatment of CHF could have contributed to the weight loss
* Tachycardia (heart rate \>120 beats/min) Minor criteria are acceptable only if they cannot be attributed to another medical condition (such as pulmonary hypertension, chronic lung disease, cirrhosis, ascites, or the nephrotic syndrome).

Exclusion Criteria:

* Patients unable to provide blood sample
* Patients unable to provide consent
* Patient with life expectancy of less than 6 months, or has major co-morbidities.
* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
* Participants who have participated in another research trial involving an investigational product in the past 30 days.
Locations (1)
  • Ottawa, Ontario, Canada